BHP87.87-2.49 (-2.76%) ▼|RIO100.08-2.59 (-2.52%) ▼|SCCO192.93+1.25 (+0.65%) ▲|601088.SS41.26-0.60 (-1.43%) ▼|601899.SS29.69-0.74 (-2.43%) ▼|NEM103.79-1.88 (-1.78%) ▼|FCX68.68-0.38 (-0.55%) ▼|GMEXICOB.MX214.21-0.49 (-0.23%) ▼|GLEN.L566.00-17.20 (-2.95%) ▼|AEM166.66-6.33 (-3.66%) ▼|ABX.TO57.08-1.35 (-2.31%) ▼|VALE15.42-0.11 (-0.71%) ▼|1211.HK80.85-1.05 (-1.28%) ▼|ANTO.L4,169.00-92.00 (-2.16%) ▼|WPM122.57-3.28 (-2.61%) ▼|3993.HK18.87-0.56 (-2.88%) ▼|AU90.87-0.05 (-0.06%) ▼|CCJ106.49+0.82 (+0.78%) ▲|FMG.AX19.97-0.35 (-1.72%) ▼|BHP87.87-2.49 (-2.76%) ▼|RIO100.08-2.59 (-2.52%) ▼|SCCO192.93+1.25 (+0.65%) ▲|601088.SS41.26-0.60 (-1.43%) ▼|601899.SS29.69-0.74 (-2.43%) ▼|NEM103.79-1.88 (-1.78%) ▼|FCX68.68-0.38 (-0.55%) ▼|GMEXICOB.MX214.21-0.49 (-0.23%) ▼|GLEN.L566.00-17.20 (-2.95%) ▼|AEM166.66-6.33 (-3.66%) ▼|ABX.TO57.08-1.35 (-2.31%) ▼|VALE15.42-0.11 (-0.71%) ▼|1211.HK80.85-1.05 (-1.28%) ▼|ANTO.L4,169.00-92.00 (-2.16%) ▼|WPM122.57-3.28 (-2.61%) ▼|3993.HK18.87-0.56 (-2.88%) ▼|AU90.87-0.05 (-0.06%) ▼|CCJ106.49+0.82 (+0.78%) ▲|FMG.AX19.97-0.35 (-1.72%) ▼|
31.3 C
New York
Thursday, June 18, 2026

Tag: blood

newssourceFORcompanyinformationcontent1marketreleases

Wondercide Launches RESCUE™ –Breakthrough Pet Wellness Solutions Powered by Hypochlorous Acid

"Miracle Molecule" in cosmetic and beauty industries now available in advanced pet care line from Wondercide called RESCUE™. AUSTIN, Texas, July 23, 2025 /PRNewswire/ --...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC

Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services MCLEAN, Va., July 22,...

Ignored and Undiagnosed: Sleep Apnea Threatens Women’s Cognitive Health

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...

Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas, July 22, 2025 /PRNewswire/ -- Caris Life...

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

OMRON Healthcare Singapore partners with bolttech and QBE to launch innovative embedded health solution

The comprehensive subscription programme offers OMRON customers in Singapore access to personalised health protection and insights SINGAPORE, July 22, 2025 /PRNewswire/ -- Global insurtech bolttech...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Safety Shot Announces Pricing of $10.6 Million Registered Direct Offering

SCOTTSDALE, AZ, July 21, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today announced the pricing of a registered direct offering with an institutional investor for the purchase and sale of 28,648,648 shares of its common stock at a purchase price of $0.37 per share.

Semler Scientific® Announces Earnings Release Date and Live Video Webinar for Second Quarter 2025 Financial Results

CAMPBELL, Calif., July 21, 2025 /PRNewswire/ --Semler Scientific, Inc. (Nasdaq: SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve...

Summer Pitch: How to Prevent Baseball Injuries This Season

The American Academy of Orthopaedic Surgeons share expert tips to help players stay safe on the field ROSEMONT, Ill., July 21, 2025 /PRNewswire/ -- Baseball...

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBlood

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers